Alkermes (ALKS) announced the publication of data from the Vibrance-1 phase 2 study of alixorexton in adults with narcolepsy type 1, or NT1, in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor agonist i… [1008 chars]